P501: CLI120-001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE

• C. Abboud,
• Z. Jan Maciej,
• G. Borthakur,
• S. Solomon,
• B. Howard,
• T. Bradley,
• E. Mouhayar,
• N. Angelosanto,
• H. Nogai,
• A. Glasmacher,
• R. Dudziak,
• K. Brzozka,
• T. Rzymski,
• P. Littlewood,
• E.-L. Maranda

Affiliations

C. Abboud

1 Division of Oncology, Washington University In Saint Louis, Saint Louis, United States of America

Z. Jan Maciej

2 Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland

G. Borthakur

3 Department of Leukemia, MD Anderson Cancer Center, Houston

S. Solomon

4 Blood and Marrow Transplant Leukemia and Immunotherapy Unit, Northside Hospital, Atlanta

B. Howard

5 Sarah Cannon Research Institute, Sarah Cannon, Nashville

T. Bradley

6 Division of Hematology, University of Miami Health System, Miami

E. Mouhayar

7 Department of Cardiology, MD Anderson Cancer Center, Houston, United States of America

N. Angelosanto

8 CLINICAL DEVELOPMENT, Ryvu therapeutics, Krakow, Poland

H. Nogai

8 CLINICAL DEVELOPMENT, Ryvu therapeutics, Krakow, Poland

A. Glasmacher

9 Dep. of Internal Medicine III, University Clinic Bonn, Bonn, Germany

R. Dudziak

8 CLINICAL DEVELOPMENT, Ryvu therapeutics, Krakow, Poland

K. Brzozka

10 Research & Preclinical Development

T. Rzymski

10 Research & Preclinical Development

P. Littlewood

11 DMPK Department, Ryvu Therapeutics, Krakow

E.-L. Maranda

12 Deaprtment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland